Compare T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Inverse MSTR Daily Target ETF vs Recursion Pharmaceuticals Inc — how do they compare? T-Rex 2X Inverse MSTR Daily Target ETF trades at $10.59, while Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B). The key difference: T-Rex 2X Inverse MSTR Daily Target ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| MSTZ | RXRX | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $27.92 | $6.79 |
52-Week Low | $3.50 | $2.84 |
Market Cap | — | $1.53B |
Enterprise Value | — | $946.50M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
